Nabeel Kajihara
Sapporo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Augmented interferon regulatory factor 7 axis in whole tumor cell vaccines prevents tumor recurrence by inducing interferon gamma-secreting B cells.
Journal: Oncoimmunology
Published: May 26, 2023
Blocking of oestrogen signals improves anti-tumour effect regardless of oestrogen receptor alpha expression in cancer cells.
Journal: British journal of cancer
Published: January 31, 2023
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
Journal: Journal of gynecologic oncology
Published: June 23, 2022
Erratum: Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Journal: iScience
Published: January 14, 2022
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: January 12, 2022
Interleukin-34: a key molecule in the tumor microenvironment
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: September 09, 2021
Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.
Journal: Breast cancer (Tokyo, Japan)
Published: March 04, 2020
Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.
Journal: iScience
Published: February 24, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026